Sentences with phrase «clinical cancer research for»

Not exact matches

The company points to a simple resource allocation problem that's hindered the most effective patient care: the fact that it is physically impossible for oncologists to keep track of every study, every clinical trial, and every breakthrough in the wildly stratified world of cancer research.

Science and Technology — Subject: Clinical trials Witness (es): Professor Karol Sikora, Medical Director of Cancer Partners UK and Dean, University of Buckingham Medical School and Simon Denegri, NIHR National Director for Public Participation and Engagement in Research and Chair, INVOLVE; Tracey Brown, Managing Director, Sense About Science and Dr Helen Jamison, Deputy Director, Science Media Centre; Sir Kent Woods, Chief Executive,, Dr Janet Wisely, Chief Executive, Health Research Authority, Bill Davidson, Acting Deputy Director and Head of Research Standards and Support, Department of Health and Peter Knight, Deputy Director, Head of Research Information and Intelligence, Department of Health Location: Room 8, Palace of Westminster

The facility is involved in drug development and conducts clinical research for cancer treatment.

These attention - getting stories about cancer immunotherapy underline the vast career opportunities in academic, clinical, and industry research for those entering this field.

Future resources from the NCI Center for Cancer Genomics (CCG), which oversees TCGA and other activities, will support more translationally focused research, including databases with genomic information on clinical samples linked to outcomes of their patient donors.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Hcancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HCancer Center at UC San Diego Health.

The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a # 10 million investment from Cancer Researcancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a # 10 million investment from Cancer ResearCancer Research UK.

Other UT Southwestern faculty members who contributed to this research are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Mresearch are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Medicine;

Watercress extract taken multiple times a day significantly inhibits the activation of a tobacco - derived carcinogen in cigarette smokers, researchers at the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, demonstrated in a phase II clinical trial presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.

UTSW co-authors include: Co-lead author Maria Winter, a research associate; Dr. Luisella Spiga, a postdoctoral researcher; visiting fellow Lisa Büttner; graduate students Elizabeth Hughes and Caroline Gillis, all of Microbiology; Dr. Breck Duerkop, Instructor, Immunology; Cassie Behrendt, a research technician, Immunology; Dr. Lora Hooper, Professor and Chair of Immunology with appointments in Microbiology and in the Center for the Genetics of Host Defense, a HHMI Investigator and holder of the Jonathan W. Uhr, M.D. Distinguished Chair in Immunology, and the Nancy Cain and Jeffrey A. Marcus Scholar in Medical Research, in Honor of Dr. Bill S. Vowell; Dr. Luis Sifuentes - Dominguez, Instructor of Pediatrics; Dr. Kayci Huff - Hardy, clinical fellow, Internal Medicine in the Division of Digestive and Liver Diseases; Dr. Andrew Koh, Associate Professor of Pediatrics and Microbiology and in the Harold C. Simmons Comprehensive Cancer Center as well as Director of Pediatric Hematopoietic Stem Cell Transplantation at Children's Health; and Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of the Division of Digestive and Liver Dresearch associate; Dr. Luisella Spiga, a postdoctoral researcher; visiting fellow Lisa Büttner; graduate students Elizabeth Hughes and Caroline Gillis, all of Microbiology; Dr. Breck Duerkop, Instructor, Immunology; Cassie Behrendt, a research technician, Immunology; Dr. Lora Hooper, Professor and Chair of Immunology with appointments in Microbiology and in the Center for the Genetics of Host Defense, a HHMI Investigator and holder of the Jonathan W. Uhr, M.D. Distinguished Chair in Immunology, and the Nancy Cain and Jeffrey A. Marcus Scholar in Medical Research, in Honor of Dr. Bill S. Vowell; Dr. Luis Sifuentes - Dominguez, Instructor of Pediatrics; Dr. Kayci Huff - Hardy, clinical fellow, Internal Medicine in the Division of Digestive and Liver Diseases; Dr. Andrew Koh, Associate Professor of Pediatrics and Microbiology and in the Harold C. Simmons Comprehensive Cancer Center as well as Director of Pediatric Hematopoietic Stem Cell Transplantation at Children's Health; and Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of the Division of Digestive and Liver Dresearch technician, Immunology; Dr. Lora Hooper, Professor and Chair of Immunology with appointments in Microbiology and in the Center for the Genetics of Host Defense, a HHMI Investigator and holder of the Jonathan W. Uhr, M.D. Distinguished Chair in Immunology, and the Nancy Cain and Jeffrey A. Marcus Scholar in Medical Research, in Honor of Dr. Bill S. Vowell; Dr. Luis Sifuentes - Dominguez, Instructor of Pediatrics; Dr. Kayci Huff - Hardy, clinical fellow, Internal Medicine in the Division of Digestive and Liver Diseases; Dr. Andrew Koh, Associate Professor of Pediatrics and Microbiology and in the Harold C. Simmons Comprehensive Cancer Center as well as Director of Pediatric Hematopoietic Stem Cell Transplantation at Children's Health; and Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of the Division of Digestive and Liver DResearch, in Honor of Dr. Bill S. Vowell; Dr. Luis Sifuentes - Dominguez, Instructor of Pediatrics; Dr. Kayci Huff - Hardy, clinical fellow, Internal Medicine in the Division of Digestive and Liver Diseases; Dr. Andrew Koh, Associate Professor of Pediatrics and Microbiology and in the Harold C. Simmons Comprehensive Cancer Center as well as Director of Pediatric Hematopoietic Stem Cell Transplantation at Children's Health; and Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of the Division of Digestive and Liver Diseases.

The German biotech CureVac, for example, has brought mRNA - based vaccines for rabies and cancer to clinical trials, and Karikó now heads a research team at BioNTech in Mainz, Germany, that focuses on mRNA - based drugs.

According to the University of Utah's drug information service, 198 drug shortages had been reported in the United States by late August this year, 15 of which are cancer drugs required for clinical research.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

«Our research paves the way for future clinical trials that screen for AIM2 expression in colon cancer and possibly other cancers to identify patients who may potentially benefit from personalized anti-Akt therapy,» Wilson said.

New research findings from Uppsala University and Uppsala Clinical Research Center show that smoking alters several genes that can be associated with health problems for smokers, such as increased risk for cancer and dresearch findings from Uppsala University and Uppsala Clinical Research Center show that smoking alters several genes that can be associated with health problems for smokers, such as increased risk for cancer and dResearch Center show that smoking alters several genes that can be associated with health problems for smokers, such as increased risk for cancer and diabetes.

Connecting a global network of more than 40,000 cancer professionals, the society serves as the leading resource for best practices in clinical oncology research and academic and community practices.

Study co-leader Wyndham Wilson, M.D., Ph.D., NCI Center for Cancer Research, added, «This is the first clinical study to demonstrate the importance of precision medicine in lymphomas.»

Meanwhile, his research teams are moving several other novel therapies toward clinical trials, each of which has potential for use in the synergistic model of cancer treatment that Black believes will offer the best hope for his patients.

Principal investigator E. Shelley Hwang, M.D., chief of breast surgery at the Duke Cancer Institute and vice chair of research in the Duke University Department of Surgery, will lead the study through the cooperative group, The Alliance for Clinical Trials in Oncology.

«Our findings are encouraging, as they suggest that entolimod can be safely combined with other chemotherapeutic, targeted or immunotherapeutic agents as treatment for advanced and very hard - to - treat cancers,» notes Dr. Adjei, who is Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park.

«Despite the presence of a universal health insurance system in Ontario, our research highlights the persistence of significant health disparities in breast cancer screening, particularly for women who are more vulnerable due to severe disability, multiple chronic conditions, low income and lower education,» said Dr. Guilcher, who has a PhD in Clinical Epidemiology at the Institute of Health Policy, Management and Evaluation, University of Toronto.

The method can be applied to a range of fields, including clinical settings and fundamental biology research for cancer and other diseases.

«The exciting research results being presented today underscore how transplants are becoming an increasingly successful treatment option for more patients with blood cancer than ever before,» said Jeffrey Miller, MD, moderator of the press conference and Deputy Director of the Masonic Cancer Center and the Clinical and Translational Sciences Institute at the University of Minnesota in Minneacancer than ever before,» said Jeffrey Miller, MD, moderator of the press conference and Deputy Director of the Masonic Cancer Center and the Clinical and Translational Sciences Institute at the University of Minnesota in MinneaCancer Center and the Clinical and Translational Sciences Institute at the University of Minnesota in Minneapolis.

«We still have a long way to go and many challenges to overcome before we will have therapies that are ready for clinical use, but this is a significant first step in the process,» says Emdad, member of the Cancer Molecular Genetics research program at Massey, assistant professor in the VCU Department of Human and Molecular Genetics and member of the VIMM.

His research on attaching selenium to the leading clinical chemotherapeutic monoclonal antibody for a type of breast cancer shows it can more effectively kill the cancer cells, he reports.

Screening for colorectal cancer based on age alone may contribute to both underuse and overuse of the tests among older patients, according to a study by investigators at the University of Michigan and the Veterans Affairs Center for Clinical Management Research.

Her research is both translational and clinical in nature and centers on the human genetics of healthy skin aging and diseases related to aging skin, including new treatments for advanced basal cell skin cancers.

During the webinar, our expert panel of researchers will discuss: • Strategies and technologies for successful cancer biomarker discovery through robust detection and analysis of miRNAs in biofluids • Research into analytic and biological variables that impact miRNA measurements in serum and plasma from the clinical pathologist's point of view • The novel application of miRNAs in serum as biomarkers of aging and chronic disease • The answers to questions submitted by the live, online viewers.

But this is early laboratory research and the next stage is for clinical trials to confirm whether resveratrol has the same effects in people at high risk of bowel cancer.»

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

Aedin Cassidy, Sheila Bingham and John Cummings of the Medical Research Council's Dunn Clinical Nutrition Centre in Cambridge are the first researchers to look for links between consumption of starch and cancer of the large bowel on an international scale.

Cherny, an oncologist and palliative medicine specialist who is chair of humanistic medicine at Shaare Zedek Medical Centre, Jerusalem, Israel, added: «The designation also indicates that the centre is not only providing a clinical service but that it has programmes developed both to push the boundaries of knowledge through research and to teach the essential skills required for the provision of palliative care to cancer patients.»

Professor Tim Maughan, Clinical Director of the Cancer Research UK / Medical Research Council Oxford Institute for Radiation Oncology, said «This novel and exciting finding provides a new scientific basis for precision targeting of some cancers which are currently very difficult to treat, and we are now taking these findings into clinical trialsClinical Director of the Cancer Research UK / Medical Research Council Oxford Institute for Radiation Oncology, said «This novel and exciting finding provides a new scientific basis for precision targeting of some cancers which are currently very difficult to treat, and we are now taking these findings into clinical trialsclinical trials.»

The work is published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Olivier Rixe, MD, PhD, Associate Center Director for Clinical Research at the UNM Comprehensive Cancer Center, serves as a National Principal Investigator for these clinicalClinical Research at the UNM Comprehensive Cancer Center, serves as a National Principal Investigator for these clinicalclinical trials.

Barrett, who directed NCI's Center for Cancer Research while Stevenson was a postdoc there, appointed her as Novartis's associate director of clinical research for oncology bioResearch while Stevenson was a postdoc there, appointed her as Novartis's associate director of clinical research for oncology bioresearch for oncology biomarkers.

New research on innovative immunotherapies for advanced or high - risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO).

NCCC's leading pancreatic cancer research experts highlight groundbreaking research projects and clinical trials underway for this challenging cancer, and offer thoughts on what the future holds.

The goal of the Center for Clinical and Translational Sciences (CCTS) is to facilitate clinical and translational research at UTHealth, The University of Texas MD Anderson Cancer Center and the Memorial Hermann HospitalClinical and Translational Sciences (CCTS) is to facilitate clinical and translational research at UTHealth, The University of Texas MD Anderson Cancer Center and the Memorial Hermann Hospitalclinical and translational research at UTHealth, The University of Texas MD Anderson Cancer Center and the Memorial Hermann Hospital System.

«The idea that antioxidants are good for you has been so strong that there have been clinical trials done in which cancer patients were administered antioxidants,» added Dr. Morrison, who is also a CPRIT Scholar in Cancer Research and a Howard Hughes Medical Institute Investicancer patients were administered antioxidants,» added Dr. Morrison, who is also a CPRIT Scholar in Cancer Research and a Howard Hughes Medical Institute InvestiCancer Research and a Howard Hughes Medical Institute Investigator.

«RNAi therapies are a unique approach to cancer treatment as they have the potential to «turn off» the genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&cancer treatment as they have the potential to «turn off» the genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.&cancer cell to block the expression of specific proteins involved in tumor growth.»

In its twenty years of operation, the NRSA program has made it possible for many thousands of talented individuals in the basic biomedical, behavioral, and clinical sciences to sharpen their research skills and to apply those skills to topics of special concern to the nation, such as aging, hypertension, the genetic basis of disease, acquired immune deficiency syndrome (AIDS), cancer, environmental toxicology, nutrition and health, and substance abuse.

A type of kidney tumor can progress along one of three distinct evolutionary pathways, each with different clinical outcomes, according to research presented Sunday (April 15) at the American Association for Cancer Research (AACR) meeting in research presented Sunday (April 15) at the American Association for Cancer Research (AACR) meeting in Research (AACR) meeting in Chicago.

The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of HCancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Hcancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of HCancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes ofResearch Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes ofresearch at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.

The study is published in the journal Cancer Cell, with funding for the UK research team coming from the Kimmel Cancer Foundation, Cancer Research UK, The Marie Curie Actions Programme and a Scottish Senior Clinical Research Felresearch team coming from the Kimmel Cancer Foundation, Cancer Research UK, The Marie Curie Actions Programme and a Scottish Senior Clinical Research FelResearch UK, The Marie Curie Actions Programme and a Scottish Senior Clinical Research FelResearch Fellowship.

About the Anna - Maria Kellen Clinical Accelerator The Anna - Maria Kellen Clinical Accelerator, the clinical research program of the Cancer Research Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innClinical Accelerator The Anna - Maria Kellen Clinical Accelerator, the clinical research program of the Cancer Research Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innClinical Accelerator, the clinical research program of the Cancer Research Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innclinical research program of the Cancer Research Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innresearch program of the Cancer Research Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innovCancer Research Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innResearch Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innresearch and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innovcancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innclinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innresearch ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innovation.

The Department of Translational Hematology and Oncology Research (THOR) conducts cancer research to develop and make available novel diagnostic tools, targeted therapies and clinical trials for direct use in patieResearch (THOR) conducts cancer research to develop and make available novel diagnostic tools, targeted therapies and clinical trials for direct use in patieresearch to develop and make available novel diagnostic tools, targeted therapies and clinical trials for direct use in patient care.

Georgia CORE aims to increase the skills and competencies of the cancer research workforce; raise awareness about the opportunities and benefits of clinical trials; incorporate the perspectives of patients and survivors into clinical cancer research; advocate for clinical trials financing, regulatory improvement and resource development; promote access to and enrollment in clinical trials; and stimulate dialogue and collaboration among multi-disciplinary cancer researchers.

For more information, contact Kelly Jenkins, oncology clinical research nurse at the Georgia Cancer Center, at 706-721-1206.

With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patientsResearch Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatment and of the need for continued public support for research to bring these treatments to more patientsresearch to bring these treatments to more patients sooner.